← vista completa

Published on September 1, 2008 | http://doi.org/10.5867/medwave.2008.08.1652

Aldosterone in diabetic nephropathy

Aldosterona en nefropatía diabética

Miriam Alvo Abodovsky

This work is licensed under a Creative Commons Attribution 4.0 International License. Esta licencia permite el uso, distribución y reproducción del artículo en cualquier medio, siempre y cuando se otorgue el crédito correspondiente al autor del artículo y al medio en que se publica, en este caso, Medwave.

Authors

Miriam Alvo Abodovsky

Hospital Clínico Universidad de Chile, Santiago, Chile

Figures

Article has no figures.

Forum

No messages

History

Citation Alvo Abodovsky M. Aldosterone in diabetic nephropathy. Medwave 2008;8(08):e1652 doi: 10.5867/medwave.2008.08.1652

Submission date 01/01/1970

Acceptance date 01/01/1970

Publication date 01/09/2008

Index

Metrics

Not available at the moment.

Notes

References

  1. Hostetter TH, Ibrahim HN. Aldosterone in chronic kidney and cardiac disease. J Am Soc Nephrol. 2003 Sep;14(9):2395-401. | CrossRef | PubMed
  2. Epstein M. Aldosterone blockade: an emerging strategy for abrogating progressive renal disease. Am J Med. 2006 Nov;119(11):912-9. | CrossRef | PubMed
  3. Greene EL, Kren S, Hostetter TH. Role of aldosterone in the remnant kidney model in the rat. J Clin Invest. 1996 Aug 15;98(4):1063-8. | CrossRef | PubMed
  4. Blasi ER, Rocha R, Rudolph AE, Blomme EA, Polly ML, McMahon EG. Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int. 2003 May;63(5):1791-800. | CrossRef | PubMed
  5. Terada Y, Kobayashi T, Kuwana H, Tanaka H, Inoshita S, Kuwahara M, et al. Aldosterone stimulates proliferation of mesangial cells by activating mitogen-activated protein kinase 1/2, cyclin D1, and cyclin A.. J Am Soc Nephrol. 2005 Aug;16(8):2296-305. Epub 2005 Jun 23. | CrossRef | PubMed
  6. Han KH, Kang YS, Han SY, Jee YH, Lee MH, Han JY, et al. Spironolactone ameliorates renal injury and connective tissue growth factor expression in type II diabetic rats. Kidney Int. 2006 Jul;70(1):111-20. Epub 2006 May 24. | CrossRef | PubMed
  7. Nagase M, Shibata S, Yoshida S, Nagase T, Gotoda T, Fujita T. Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker. Hypertension. 2006 Jun;47(6):1084-93. Epub 2006 Apr 24. | CrossRef | PubMed
  8. Shibata S, Nagase M, Yoshida S, Kawachi H, Fujita T. Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1. Hypertension. 2007 Feb;49(2):355-64. Epub 2007 Jan 2. | CrossRef | PubMed
  9. Aldigier JC, Kanjanbuch T, Ma LJ, Brown NJ, Fogo AB. Regression of existing glomerulosclerosis by inhibition of aldosterone. J Am Soc Nephrol. 2005 Nov;16(11):3306-14. Epub 2005 Sep 28. | CrossRef | PubMed
  10. Sato A, Saruta T. Aldosterone breakthrough during angiotensin-converting enzyme inhibitor therapy. Am J Hypertens. 2003 Sep;16(9 Pt 1):781-8. | CrossRef | PubMed
  11. Schjoedt KJ, Rossing K, Juhl TR, Boomsma F, Rossing P, Tarnow L, et al. Beneficial impact of spironolactone in diabetic nephropathy. Kidney Int. 2005 Dec;68(6):2829-36. | CrossRef | PubMed
  12. van den Meiracker AH, Baggen RG, Pauli S, Lindemans A, Vulto AG, Poldermans D, et al. Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function. J Hypertens. 2006 Nov;24(11):2285-92. | CrossRef | PubMed
  13. Bianchi S, Bigazzi R, Campese VM. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int. 2006 Dec;70(12):2116-23. Epub 2006 Oct 11. | CrossRef | PubMed
  14. Chrysostomou A, Pedagogos E, MacGregor L, Becker GJ. Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker. Clin J Am Soc Nephrol. 2006 Mar;1(2):256-62. Epub 2006 Feb 1. | CrossRef | PubMed